Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX

Blood

Volumn 97, Issue 12, 2001, Pages 3733-3737

  Ge, Ying ^a   Powell, Sandra ^a   Van Roey, Melinda ^a   McArthur, James G ^a  

^a CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; GENE PRODUCT; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; VIRUS PARTICLE;

EID: 0035877984     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3733     Document Type: Article

References (17)

1. Jooss K, Yang Y, Fisher K, Wilson J. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers, J Virol. 1998;72:4212.
2. Brockstedt D, Podsakoff G, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman E. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999;92:67.
3. Herzog R, Yang E, Couto L, et al. Long term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector,. Nat Med. 1999;5:56.
4. Herzog R, Hagstrom J, Kung S, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-aasociated virus. Proc Natl Acad Sci U S A. 1997;94:5804.
5. Fields P, Kowalczyk D, Arruda V, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther. 2000;1:225.
6. Moskalenko M, Chen L, Roey M, et al. Epitope mapping of human anti-AAV neutralizing antibodies; implications for gene therapy and virus structure. J Virol. 2000;
7. Snyder R, Miao C, Patijn G, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270.
8. Snyder R, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors [see comments]. Nat Med. 1999;5:64.
9. Klein R, Meyer E, Peel A, et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol. 1998;150:183.
10. McCown T, Xiao X, Li J, Breese G, Samulski R. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 1996;713:99.
11. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6:1574.
12. Michou A, Christ M, Pavirani A, Mehtali M. Genetic therapy for hemophiliacs-therapeutic potential and technological limits. Transfus Clin Biol (French). 1997;4:251.
13. Kay M, Manno C, Ragni M, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257.
14. Burczynski F, Luxon B, Weisiger R. Intrahepatic blood flow distribution in the perfused rat liver: effect of hepatic artery perfusion. Am J Physiol. 1996;271:G561.
15. Jakab F, Rath Z, Schmal F, Nagy P, Faller J. The interaction between hepatic arterial and portal venous blood flows; simultaneous measurement by transit time ultrasonic volume flowmetry. Hepatogastroenterology. 1995;42:18.
16. Ternberg J, Butcher H. Blood-flow relation between hepatic artery and portal vein. Science. 1965;150:1030.
17. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther. 1999;10:1773.